Manziel enters rehab - major news for BICX

Published: Tue, 02/03/15

 

Morning again,
 
You may have heard that yesterday high profile Football player Johnny Manziel voluntarily entered rehab for alcohol abuse.
 
BICX is revolutionizing treatment for alcohol and substance abuse, and has been featured in major media outlets such as Fox Business, The Doctors, Bloomberg, Time Magazine and the New York Times.
 
And this morning, BICX announced that it is expanding the availability of its treatment...

BioCorRx, Inc. Announces Availability of its Start Fresh Program(r) for Treating Addiction in West Hartford, Connecticut

Los Angeles, Feb. 3, 2015 (GLOBE NEWSWIRE) -- BioCorRx, Inc. (BICX), developer of the Start Fresh Program, announces the opening of a new Start Fresh Recovery center in West Hartford, CT. The center will operate under a distribution arrangement with JPL, LLC. JPL holds the distribution rights to the Start Fresh Program for the state of Connecticut. This is their second opening in the state. Their other location is located in Norwalk. "BioCorRx, Inc. is pleased with the back-to-back openings of two new centers at the start of 2015, especially since one of them is a second opening by one of our licensees," stated COO & interim CEO, Brady Granier. Last week the company announced a new center will soon be open in the Dallas metropolitan area. "An additional center in the Northeast is a significant step towards broadening the accessibility of the Start Fresh program", says Mr. Granier. The center is located at 970 Farmington Ave., Suite 304, West Hartford, CT 06107. It will officially open on February 9, 2015. With the opening of this new location, there will now be a total of 12 centers across the United States offering the Start Fresh Program.

The population of Connecticut is approximately 3.5 million people, with nearly 1 million residing in Hartford County. Hartford is centrally located in the state and is a short drive to Rhode Island, Massachusetts and New York State. According to the National Survey on Drug Use and Health, Connecticut is one of the top ten states for dependence on illicit drugs. Data from the Centers for Disease Control shows excessive alcohol use in the state is responsible for nearly 900 lives lost each year, or 23,149 years of potential life lost. The CDC estimated the cost to taxpayers as a result of these fatalities is approximately $2.7 billion annually.

"Bringing effective treatment to everyone who wants it continues to be our primary goal. One of the most important aspects of our program is that it allows people to be treated within the framework of their own lives. To do that more effectively and conveniently for the patient, we want widespread availability of our program," said Mr. Granier. "A location that is conveniently accessible from multiple states and large metropolitan areas in the Northeast significantly broadens the program's potential to help families and individuals struggling with addiction."

2014 was a pivotal year for BioCorRx, Inc. Start Fresh centers saw a 402% increase in patients treated from 2013 to 2014. Over the course of 2015, the company plans to continue the process of developing more new territories with its partners.

Number of clinics at the end of each quarter offering the Start Fresh Program

-Q1, 2014 -- 5 clinics offering the Start Fresh Program

-Q2, 2014 -- 6 clinics offering the Start Fresh Program

-Q3, 2014 -- 6 clinics offering the Start Fresh Program

-Q4, 2014 -- 10 clinics offering the Start Fresh Program

-To date in Q1, 2015 - 12 clinics offering the Start Fresh Program

 
Please continue your research on BICX below and be ready to trade today.
 
ShiznitStocks.com
 
 
----------------------------------------------------------------------
 
 
Traders,
 
Ok, I really want to kick this week off on a high note. So what better way to do it than to revisit a multiple time past winner that has pulled back right to support and technical analysis looks great.
 
And best of all, BICX is in the hottest sector on Wall Street - the Biotech sector.
 
We've seen many biotechs run for triple digit gains over the past month or so, and we think BICX is about to wake up and deliver some seriously good gains.
 
BICX has pulled back right to support (but still looking very bullish), giving the opportunity for a really solid entry point.
 
The first thing I want you to do is watch this short video about BICX who were featured on Fox Business. 
 
 
In the video, Dr Manny Alvarez discusses BICX's new treatment for alcoholism, and how effective it could be.
Now, we all know the harmful effects of alcohol and the dangers its abuse can have on individuals and families. 
 
Alcohol treatment and rehabilitation is in huge demand today as alcohol addiction becomes a bigger cause for concern in today's society.
 
Similarly we have all heard stories (and may even know people) that are in and out of traditional alcohol abuse clinics. Traditional treatment programs just don't work as effectively any more.
 
BICX has developed a revolutionary alcohol treatment program with an 85% success rate, as reported by patients that have completed the program and completed routine telephone and face to face interviews.
 
This is huge for BICX, alcohol abuse suffers and their families.
 
BICX is on the leading edge of alcohol addiction, literally revolutionizing the way alcohol treatment and rehabilitation is administered. Put simply, BICX is uniquely poised to gain significant market share of the $22 billion annual alcohol treatment market in the US.
 
The company has developed a highly effective program called the Start Fresh Program(TM) consisting of two components used by various alcohol addiction clinics in the US.
 
The first component of the program consists of an outpatient implant procedure performed by a licensed physician that delivers therapeutic levels of the drug Naltrexone, an opiate antagonist that significantly reduces physical cravings for alcohol and opioids, into the body.
 
The second component of the program developed by BioCorRx is a one on one coaching program specifically tailored for the treatment of alcoholism and other substance abuse adictions.
 
Folks, traditional alcohol abuse treatment programs are money printing machines for their administrators, and they're not even as effective as they used to be.
 
So imagine my excitement to see a company like BICX develop an even more effective program for the treatment of alcohol abuse.... Now imagine the potential for BICX.
 
BICX is also gaining huge main stream media exposure...
 
Naltrexone was recently covered in Time Magazine and The New York Times.
 
BICX and/or its Start Fresh Program was recently featured on The Doctors, Bloomberg, Fox Business News, and in multiple local news segments in Los Angeles, San Francisco, San Diego, New York and others. 
 
And according to their website, BICX is cash flow positive for the first time in its history due to increase in license fees, royalties and direct sales.
 
To learn more about BICX and their alcohol treatment program, visit their website at www.biocorrx.com
 
To find out more about BICX as a potentially lucrative investment at these levels, check out the amazing value proposition.
 
Now, while you digest how truly exciting BICX as a company is, let's focus on the chart, which tells an equally impressive story.
 
 
As you can see, BICX has a history of making big moves higher. Back in September it gained 50% in two days. And in November it gained almost 100% in one day.
 
We think its time for BICX to make another run higher. And this time could be even bigger, especially if it can break through $0.01.
 
BICX in the News
 
Now combine the BICX fundamentals, its story and business model, with its technical's, and we have an excellent candidate to make us some serious money.
 
Do not sleep on this one as it could move quickly over the coming days.
 
 
www.ShiznitStocks.com
 

Disclaimer

Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. For full disclaimer click here.
ShiznitStocks.com employees are not registered as an Investment Adviser in any jurisdiction whatsoever. The disclaimer is to be read and fully understood before using our site, or joining our email list. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein.  Instead ShiznitStocks.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. ShiznitStocks.com does not offer such advice or analysis, and ShiznitStocks.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, ShiznitStocks.com has relied upon information supplied by its customers, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, ShiznitStocks.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents have not completed any due diligence or research on the companies advertised herein and disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. ShiznitStocks.com is not responsible for any claims made by the companies advertised herein. ShiznitStocks.com may receive compensation and its employees and affiliates may own stock that they have purchased in the open market either prior, during, or after the release of the companies profile which is an inherent conflict of interest in ShiznitStocks.com statements and opinions and such statements and opinions cannot be considered independent. ShiznitStocks.com reserves the right to buy and sell shares of the profiled company on the open market before, during or after the release of the company profile. In such an event, ShiznitStocks.com will not update its disclaimer to reflect any shares bought or sold on the open market during the profile coverage. ShiznitStocks.com and its management may benefit from any increase in the share price of the profiled companies and hold the right to sell the shares bought at any given time including shortly after the release of the companies profile. ShiznitStocks.com has been compensated two thousand dollars via electronic transfer from a non-affiliated third party for the profile of BICX. ShiznitStocks.com may on occasion accept compensation in restricted or free-trading shares for it's marketing services of the company being profiled, and the third party that might have compensated ShiznitStocks.com may hold free-trading shares of the company being profiled and could very well be selling shares of the companies stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.  If ShiznitStocks.com ever accepts compensation in the form of restricted or free trading shares of the company being profiled and decides to sell these shares into the public market at any time before, during, or after the release of the companies profile our disclaimer will be updated accordingly reflecting the current position of those free trading shares received as compensation for our services.